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Introduction
Familial Mediterranean Fever (FMF) is a periodic fever
syndrome characterized by recurrent episodes of fever and
serosal inflammation .The diagnosis is still based on
clinical criteria. No laboratory test is diagnostic of FMF.
During the attacks increased C reactive protein (CRP),
serum amyloid A (SAA), fibrinogen, beta 2 microglobulin,
erythrocyte sedimentation rate (ESR) and leukocytosis is
observed. The increased levels of SAA in patients with
FMF during the attack free period have been reported as a
sign of subclinical inflammation. Also, studies have shown
that during the attack the sensitivity of SAA and CRP was
similar.
Objectives
The aim of this study was to evaluate the sensitivity of SAA
and other acute phase reactants in the diagnosis of FMF.
Methods
We reviewed the medical files of 100 patients with FMF
followed up in our center in which SAA was measured;
mutation analysis was performed and yet untreated. The
diagnosis of FMF was established according to Livneh and
Yalçınkaya criteria. Patients were divided according to the
presence or absence of attack while the SAA measurement
was performed. The level of white blood cells (WBC), ESR,
CRP, fibrinogen and platelets that measured simulta-
neously with SAA were recorded. For each parameter the
level above the normal range accepted as increased.
Results
Thirty one patients were evaluated during the FMF attack
and 69 patients were evaluated during the attack free
period. The median levels (minimum, maximum) during
the attack: SAA 178 (5 - 1720) mg/L, CRP 4.5 (1 – 15.9)
mg/dl, ESR 29 (4 – 88) mm/hour, fibrinogen 4.5
(2.2 – 8.1) g/L, WBC 9100 (3910 - 26700) /mm3 platelets
343000 (146000 - 694000) /mm3 ; during the attack free
period: SAA 20 (1 - 351) mg/L, CRP 0.2 (0.1 – 7.6) mg/dl,
ESR 7 (1 – 48) mm/hour, fibrinogen 3.3 (1.6 – 6.5) g/L,
WBC 7480 (3730 - 20000) /mm3 platelets 325000 (173000
- 528000) /mm3 . The sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV)
were calculated for all parameters. (Table 1)
Table 1 Sensitivity, specificity, positive and negative
predictive values of acute phase reactans for predicting
FMF attack
Conclusion
Decreased specificity and PPV of SAA in predicting
FMF attack gave the impression that SAA levels during
the attack free period in FMF patient is increased. In
this respect it is concluded that SAA can be used as an
independent laboratory parameter to support FMF
diagnosis.
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Table 1 Sensitivity, specificity, positive and negative
predictive values of acute phase reactans for predicting
FMF attack
Sensitivity Specificity PPV NPV
SAA 96% 28% 37% 95%
ESR 64% 88% 71% 84%
CRP 83% 85% 72% 92%
Fibrinogen 58% 82% 60% 81%
WBC 45% 81% 51% 76%
Platelets 25% 88% 50% 72%
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